title: Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.
abstract: Lamivudine, adefovir, telbivudine, and entecavir are nucleoside analogues that can inhibit hepatitis B virus replication and are licensed in China by the Food and Drug Administration. This study presents the cases of 2 patients who were chronically infected with HBV and suffered hepatic failure resulting from withdrawal of telbivudine and adefovir, respectively.
authors: Department of Infectious Disease, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors: Junshuai
authors: J
authors: Wang
authors: Minxin
authors: M
authors: Wang
authors: Yuancheng
authors: Y
authors: Huang
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006147:Guanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000473:pathology*; D006651:Histocytochemistry; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D017114:Liver Failure, Acute / Q000209:etiology* / Q000473:pathology / Q000821:virology*; D016031:Liver Transplantation; D008297:Male; D055118:Medication Adherence; D009336:Necrosis; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D000077712:Telbivudine; D013936:Thymidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D000077712:Telbivudine; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; C053001:adefovir; D000225:Adenine; D013936:Thymidine